{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T22:41:59Z","timestamp":1776206519892,"version":"3.50.1"},"reference-count":22,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,5,18]],"date-time":"2022-05-18T00:00:00Z","timestamp":1652832000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Both sodium-glucose co-transporter-2 (SGLT-2) inhibitors and angiotensin receptor-neprilysin inhibitor (ARNI) were recommended to treat heart failure with reduced ejection fraction (HFrEF). However, no trial was conducted to assess the efficacy and safety of the combined therapy of SGLT-2 inhibitors and ARNI in patients with HFrEF.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We performed a meta-analysis of the prespecified subgroups from DAPA-HF and EMPEROR-Reduced trials. The primary endpoint was the composite risk of cardiovascular death or hospitalization for heart failure. The risk of cardiovascular death, all-cause death, a composite of serious adverse renal outcomes, and volume depletion were also estimated.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The risk of the composite of cardiovascular death or hospitalization for heart failure was reduced in combined therapy of SGLT-2 inhibitors and ARNI, compared with ARNI monotherapy (RR.68, 95% CI.53 to.85, <jats:italic>P<\/jats:italic> = 0.001). When compared with SGLT-2 inhibitors monotherapy, the events of cardiovascular death (RR.64, 95% CI.46 to 0.87, <jats:italic>P<\/jats:italic> = 0.005) and all-cause death (RR.72, 95% CI.55 to.94, <jats:italic>P<\/jats:italic> = 0.01) were significantly less in combined therapy, accompanied by elevated incidence of volume depletion (RR 1.55, 95% CI 1.22 to 1.96, <jats:italic>P<\/jats:italic> = 0.0003).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Combined therapy has additional benefits over monotherapy in patients with HFrEF, however, it is accompanied by a possibly higher risk of volume depletion.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fcvm.2022.882089","type":"journal-article","created":{"date-parts":[[2022,5,18]],"date-time":"2022-05-18T05:26:04Z","timestamp":1652851564000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["The Efficacy and Safety of the Combined Therapy of Sodium-Glucose Co-Transporter-2 Inhibitors and Angiotensin Receptor-Neprilysin Inhibitor in Patients With Heart Failure With Reduced Ejection Fraction: A Meta-Analysis of the EMPEROR-Reduced and DAPA-HF Sub-Analysis"],"prefix":"10.3389","volume":"9","author":[{"given":"Yanxia","family":"Lin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huanrui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shijie","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ling","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinyang","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoou","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen","family":"Tian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,5,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin\u2013Neprilysin inhibition vs. enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1056\/NEJMoa1812851","article-title":"Angiotensin-Neprilysin inhibition in acute decompensated heart failure","volume":"380","author":"Velazquez","year":"2019","journal-title":"N Engl J Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1253\/circj.CJ-20-0854","article-title":"Efficacy and safety of sacubitril\/valsartan in Japanese patients with chronic heart failure and reduced ejection fraction - results from the PARALLEL-HF study","volume":"85","author":"Tsutsui","year":"2021","journal-title":"Circ J."},{"key":"B4","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1002\/ejhf.2076","article-title":"OUTSTEP-HF: randomised controlled trial comparing short-term effects of sacubitril\/valsartan versus enalapril on daily physical activity in patients with chronic heart failure with reduced ejection fraction","volume":"23","author":"Piepoli","year":"2021","journal-title":"Eur J Heart Fail."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J."},{"key":"B8","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0140-6736(20)30748-0","article-title":"Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials","volume":"396","author":"Vaduganathan","year":"2020","journal-title":"Lancet."},{"key":"B9","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/S0140-6736(20)31824-9","article-title":"SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials","volume":"396","author":"Zannad","year":"2020","journal-title":"Lancet."},{"key":"B10","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1016\/j.jchf.2020.04.008","article-title":"Effect of dapagliflozin in patients with HFrEF treated with sacubitril\/valsartan: the DAPA-HF trial","volume":"8","author":"Packer","year":"2020","journal-title":"JACC Heart Fail."},{"key":"B11","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1093\/eurheartj\/ehaa968","article-title":"Influence of neprilysin inhibition on the efficacy and safety of empagliflozin in patients with chronic heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial","volume":"42","author":"Packer","year":"2021","journal-title":"Eur Heart J."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1007\/s00592-021-01757-z","article-title":"Tandem positive action of SGLT2 inhibitors and ARNI in patients with heart failure","volume":"58","author":"Napoli","year":"2021","journal-title":"Acta Diabetol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.ahj.2021.02.006","article-title":"Sodium-glucose co-transporter-2 inhibitors and sacubitril\/valsartan combination in patients with heart failure with reduced ejection fraction; does it deserve our attention?","volume":"236","author":"Patoulias","year":"2021","journal-title":"Am Heart J."},{"key":"B14","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1161\/CIRCULATIONAHA.114.013748","article-title":"Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure","volume":"131","author":"Packer","year":"2015","journal-title":"Circulation."},{"key":"B15","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.jacbts.2017.08.001","article-title":"Cardioprotective Effects of LCZ696 (Sacubitril\/Valsartan) after experimental acute myocardial infarction","volume":"2","author":"Ishii","year":"2017","journal-title":"JACC Basic Transl Sci."},{"key":"B16","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.cardfail.2017.12.010","article-title":"LCZ696 (sacubitril\/valsartan), an angiotensin-receptor neprilysin inhibitor, attenuates cardiac hypertrophy, fibrosis, and vasculopathy in a rat model of chronic kidney disease","volume":"24","author":"Suematsu","year":"2018","journal-title":"J Card Fail."},{"key":"B17","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.ejps.2018.11.037","article-title":"Sacubitril\/valsartan (LCZ696) significantly reduces aldosterone and increases cGMP circulating levels in a canine model of RAAS activation","volume":"128","author":"Mochel","year":"2019","journal-title":"Eur J Pharm Sci."},{"key":"B18","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1146\/annurev-physiol-031620-095920","article-title":"Effects of SGLT2 inhibitors on kidney and cardiovascular function","volume":"83","author":"Vallon","year":"2021","journal-title":"Annu Rev Physiol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s10741-018-9703-2","article-title":"SGLT2 inhibition and heart failure\u2014current concepts","volume":"23","author":"Custodio","year":"2018","journal-title":"Heart Fail Rev."},{"key":"B20","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1007\/s00125-018-4670-7","article-title":"SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review","volume":"61","author":"Verma","year":"2018","journal-title":"Diabetologia."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1002\/ejhf.933","article-title":"The potential role and rationale for treatment of heart failure with sodium\u2013glucose co-transporter 2 inhibitors","volume":"19","author":"Butler","year":"2017","journal-title":"Eur J Heart Fail."},{"key":"B22","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/S2213-8587(16)00052-8","article-title":"Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis","volume":"4","author":"Wu","year":"2016","journal-title":"Lancet Diabetes Endocrinol."}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2022.882089\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,18]],"date-time":"2022-05-18T05:26:07Z","timestamp":1652851567000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2022.882089\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,18]]},"references-count":22,"alternative-id":["10.3389\/fcvm.2022.882089"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2022.882089","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,18]]},"article-number":"882089"}}